{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:04:06Z","timestamp":1775556246165,"version":"3.50.1"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease worldwide and significantly increases the risk of premature death due to cardiovascular diseases. Elevated urinary albumin levels are an important clinical feature of DKD. Effective control of albuminuria not only delays glomerular filtration rate decline but also markedly reduces cardiovascular disease risk and all-cause mortality. New drugs for treating DKD proteinuria, including sodium-glucose cotransporter two inhibitors, mineralocorticoid receptor antagonists, and endothelin receptor antagonists, have shown significant efficacy. Auxiliary treatment with proprietary Chinese medicine has also yielded promising results; however, it also faces a broader scope for development. The mechanisms by which these drugs treat albuminuria in patients with DKD should be described more thoroughly. The positive effects of combination therapy with two or more drugs in reducing albuminuria and protecting the kidneys warrant further investigation. Therefore, this review explores the pathophysiological mechanism of albuminuria in patients with DKD, the value of clinical diagnosis and prognosis, new progress and mechanisms of treatment, and multidrug therapy in patients who have type 2 diabetic kidney disease, providing a new perspective on the clinical diagnosis and treatment of DKD.<\/jats:p>","DOI":"10.3389\/fphar.2024.1349022","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:01:30Z","timestamp":1722402090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["A new perspective on proteinuria and drug therapy for diabetic kidney disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Ruimin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","article-title":"Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results","volume":"37","author":"Agarwal","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrneph.2016.53","article-title":"Diabetic nephropathy: atrasentan stabilizes the endothelial glycocalyx","volume":"12","author":"Allison","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13346-019-00675-6","article-title":"Gold nanoparticles attenuate albuminuria by inhibiting podocyte injury in a rat model of diabetic nephropathy","volume":"10","author":"Alomari","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1077929","DOI":"10.3389\/fendo.2022.1077929","article-title":"Re-understanding and focusing on normoalbuminuric diabetic kidney disease","volume":"13","author":"An","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int."},{"key":"B11","unstructured":"Guidelines for diagnosis and management of diabetic kidney disease with integrated traditional Chinese and western medicine\n            AssociationC.\n          2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera-Chimal","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"","journal-title":"Nat. Rev. Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/mnh.0000000000000234","article-title":"New strategies to tackle diabetic kidney disease","volume":"25","author":"Batu Demir","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7787732","DOI":"10.1155\/2022\/7787732","article-title":"Combine and conquer: with type 2 diabetes polypharmacy is essential not only to achieve glycemic control but also to treat the comorbidities and stabilize or slow the advancement of diabetic nephropathy","volume":"2022","author":"Bell","year":"2022","journal-title":"J. Diabetes Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/dom.14295","article-title":"Diabetogenic effects of cardioprotective drugs","volume":"23","author":"Bell","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"111254","DOI":"10.1016\/j.mce.2021.111254","article-title":"Renin-angiotensin system and inflammation update","volume":"529","author":"Cantero-Navarro","year":"2021","journal-title":"Mol. Cell Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"154937","DOI":"10.1016\/j.metabol.2021.154937","article-title":"SGLT-2 inhibitors as cardio-renal protective agents","volume":"127","author":"Caruso","year":"2022","journal-title":"Metabolism"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.6039\/j.issn.1001-0408.2022.17.15","article-title":"Pharmacoeconomic evaluation of Keluoxin capsule combined with chemical medicine in the treatment of diabetic kidney disease","volume":"33","author":"Chang","year":"2022","journal-title":"China Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11418-020-01452-3","article-title":"Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota","volume":"75","author":"Chen","year":"2021","journal-title":"J. Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2160518","DOI":"10.1080\/10717544.2022.2160518","article-title":"Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease","volume":"30","author":"Chen","year":"2023","journal-title":"Drug Deliv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.3390\/cells11233913","article-title":"Signaling pathways of podocyte injury in diabetic kidney disease and the effect of sodium-glucose cotransporter 2 inhibitors","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.7661\/j.cjim.20230407.070","article-title":"Effect of keluoxin capsule on early hyperfiltration in diabetic kidney disease rats based on tubuloglomerular feedback mechanism","volume":"43","author":"Chunxue","year":"2023","journal-title":"Chin. J. Integr. Traditional West. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1161\/hypertensionaha.123.21367","article-title":"Kidney renin-angiotensin system: lost in a RAS cascade","volume":"81","author":"Crowley","year":"2024","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3969\/j.issn.1006-5725.2020.05.027","article-title":"Efficacy and safety of Yishen Huashi Granule in treatment of diabetic nephropathy:a Meta analysis","volume":"36","author":"Cuiping","year":"2020","journal-title":"J. Pract. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/jrr\/rrad050","article-title":"Combining network pharmacology and in vitro and in vivo experiments to study the mechanism of Keluoxin in the treatment of radiation nephropathy","volume":"64","author":"Deng","year":"2023","journal-title":"J. Radiat. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/asn.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/pharmaceutics15030965","article-title":"SGLT2 inhibitor-dapagliflozin attenuates diabetes-induced renal injury by regulating inflammation through a CYP4A\/20-HETE signaling mechanism","volume":"15","author":"Dia","year":"2023","journal-title":"Pharmaceutics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3893853","DOI":"10.1155\/2022\/3893853","article-title":"Renal histologic findings in necropsies of type 2 diabetes mellitus patients","volume":"2022","author":"D'Marco","year":"2022","journal-title":"J. Diabetes Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"F1173","DOI":"10.1152\/ajprenal.00040.2019","article-title":"Sustained, delayed, and small increments in glomerular permeability to macromolecules during systemic ET-1 infusion mediated via the ET(A) receptor","volume":"316","author":"Dolinina","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/1753-0407.13261","article-title":"Effects of SGLT2 inhibitors on patients with diabetic kidney disease: a preliminary study on the basis of podocyturia","volume":"14","author":"Durcan","year":"2022","journal-title":"J. Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1047184","DOI":"10.3389\/fphar.2023.1047184","article-title":"Niaoduqing alleviates podocyte injury in high glucose model via regulating multiple targets and AGE\/RAGE pathway: network pharmacology and experimental validation","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"121671","DOI":"10.1016\/j.lfs.2023.121671","article-title":"Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP\/TAZ activation","volume":"322","author":"Feng","year":"2023","journal-title":"Life Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/ckj\/sfz070","article-title":"Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation and study of diabetic nephropathy with atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?","volume":"12","author":"Fernandez-Fernandez","year":"2019","journal-title":"Clin. Kidney J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12916-022-02539-2","article-title":"New strategies to improve clinical outcomes for diabetic kidney disease","volume":"20","author":"Forst","year":"2022","journal-title":"BMC Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"154535","DOI":"10.1016\/j.phymed.2022.154535","article-title":"Adverse reactions of Niaoduqing granules: a systematic review and meta-analysis","volume":"109","author":"Fu","year":"2023","journal-title":"Phytomedicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.19381\/j.issn.1001-7585.2022.24.019","article-title":"Efficacy analysis of Niaoduqing granule combined with benazepril in patients with diabetic nephropathy","volume":"35","author":"Gang","year":"2022","journal-title":"J. Med. Theory Pract."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1681\/asn.2015091070","article-title":"Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx","volume":"27","author":"Garsen","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13300-022-01276-2","article-title":"Review of SGLT2i for the treatment of renal complications: experience in patients with and without T2D","volume":"13","author":"Gonz\u00e1lez-Albarr\u00e1n","year":"2022","journal-title":"Diabetes Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"i13","DOI":"10.1093\/ndt\/gfz237","article-title":"Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease","volume":"35","author":"G\u00f3rriz","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113548","DOI":"10.1016\/j.jep.2020.113548","article-title":"Huangkui capsule in combination with metformin ameliorates diabetic nephropathy via the Klotho\/TGF-\u03b21\/p38MAPK signaling pathway","volume":"281","author":"Gu","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"eabc6967","DOI":"10.1126\/scisignal.abc6967","article-title":"Mechanical activation of TRPV4 channels controls albumin reabsorption by proximal tubule cells","volume":"13","author":"Gualdani","year":"2020","journal-title":"Sci. Signal"},{"key":"B50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.therap.2019.10.001","article-title":"Polypharmacy: a general review of definitions, descriptions and determinants","volume":"75","author":"Guillot","year":"2020","journal-title":"Therapie"},{"key":"B51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/cells9010044","article-title":"TRPC channels in proteinuric kidney diseases","volume":"9","author":"Hall","year":"2019","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","first-page":"116257","DOI":"10.1016\/j.jep.2023.116257","article-title":"Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the \"gut-kidney axis","volume":"307","author":"Han","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.phymed.2018.12.021","article-title":"Huangkui capsule alleviates renal tubular epithelial-mesenchymal transition in diabetic nephropathy via inhibiting NLRP3 inflammasome activation and TLR4\/NF-\u03baB signaling","volume":"57","author":"Han","year":"2019","journal-title":"Phytomedicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/13543784.2020.1811231","article-title":"Novel therapeutic agents for the treatment of diabetic kidney disease","volume":"29","author":"Hartman","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1175310","DOI":"10.3389\/fphar.2023.1175310","article-title":"Economic evaluation of bailing capsules for patients with diabetic nephropathy in China","volume":"14","author":"He","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.kint.2023.03.037","article-title":"Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials","volume":"104","author":"Heerspink","year":"2023","journal-title":"Kidney Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/s0140-6736(19)30772-x","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1681\/asn.2021030391","article-title":"Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: a prespecified analysis from the SONAR trial","volume":"32","author":"Heerspink","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.3390\/cells11182917","article-title":"Diabetic proteinuria revisited: updated physiologic perspectives","volume":"11","author":"Heyman","year":"2022","journal-title":"Cells"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0192800","DOI":"10.1371\/journal.pone.0192800","article-title":"The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy","volume":"13","author":"Huang","year":"2018","journal-title":"PLoS One"},{"key":"B61","doi-asserted-by":"publisher","first-page":"114989","DOI":"10.1016\/j.biopha.2023.114989","article-title":"Huangqi-Danshen decoction reshapes renal glucose metabolism profiles that delays chronic kidney disease progression","volume":"164","author":"Huang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"468","DOI":"10.13683\/j.wph.2023.05.011","article-title":"Study on active ingredients and molecular mechanism of keluoxin in treatment of diabetic kidney disease based on network pharmacology and molecular docking","volume":"44","author":"Huimin","year":"2023","journal-title":"World Clin. Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1152\/physrev.00047.2017","article-title":"CLC chloride channels and transporters: structure, function, physiology, and disease","volume":"98","author":"Jentsch","year":"2018","journal-title":"Physiol. Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.7150\/thno.80435","article-title":"Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease","volume":"13","author":"Jiang","year":"2023","journal-title":"Theranostics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.kint.2021.04.029","article-title":"Central and peripheral arterial diseases in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"100","author":"Johansen","year":"2021","journal-title":"Kidney Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3803\/EnM.2022.1629","article-title":"Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease","volume":"38","author":"Kim","year":"2023","journal-title":"Endocrinol. Metab. Seoul."},{"key":"B70","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4093\/dmj.2022.0209","article-title":"Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"107954","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors","volume":"32","author":"Kogot-Levin","year":"2020","journal-title":"Cell Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"728256","DOI":"10.3389\/fphar.2022.728256","article-title":"Chinmedomics strategy for elucidating the pharmacological effects and discovering bioactive compounds from keluoxin against diabetic retinopathy","volume":"13","author":"Kong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jacc.2012.11.071","article-title":"Outcomes associated with microalbuminuria: effect modification by chronic kidney disease","volume":"61","author":"Kovesdy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.3390\/ijms25074035","article-title":"Renin-angiotensin-aldosterone system: from history to practice of a secular topic","volume":"25","author":"Ksiazek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the national kidney foundation and the US Food and drug administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/ph15121494","article-title":"Renal proximal tubular cells: a new site for targeted delivery therapy of diabetic kidney disease","volume":"15","author":"Li","year":"","journal-title":"Pharm. (Basel)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.2147\/dddt.S364069","article-title":"Effects of uremic clearance granules on p38 MAPK\/NF-\u03baB signaling pathway, microbial and metabolic profiles in end-stage renal disease rats receiving peritoneal dialysis","volume":"16","author":"Li","year":"","journal-title":"Drug Des. Devel Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"656621","DOI":"10.3389\/fendo.2021.656621","article-title":"Efficacy and safety of tripterygium glycoside in the treatment of diabetic nephropathy: a systematic review and meta-analysis based on the duration of medication","volume":"12","author":"Li","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1053\/j.jrn.2019.03.083","article-title":"Clinical efficacy and safety of jinshuibao combined with ACEI\/ARB in the treatment of diabetic kidney disease: a meta-analysis of randomized controlled trials","volume":"30","author":"Li","year":"2020","journal-title":"J. Ren. Nutr."},{"key":"B81","doi-asserted-by":"publisher","first-page":"962606","DOI":"10.3389\/fphar.2022.962606","article-title":"Yi-Shen-Hua-Shi granules inhibit diabetic nephropathy by ameliorating podocyte injury induced by macrophage-derived exosomes","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e21137","DOI":"10.1097\/md.0000000000021137","article-title":"A randomized controlled clinical trial study protocol of Liuwei Dihuang pills in the adjuvant treatment of diabetic kidney disease","volume":"99","author":"Liao","year":"2020","journal-title":"Med. Baltim."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.2337\/dc22-0966","article-title":"Can the artificial intelligence system for urine microalbuminuria detection monitor the progression of diabetic kidney disease in the clinical laboratory?","volume":"45","author":"Lin","year":"2022","journal-title":"Diabetes Care"},{"key":"B84","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"B85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/etm.2022.11726","article-title":"Role of ion channels in the mechanism of proteinuria (Review)","volume":"25","author":"Liu","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3969\/j.issn.1005.9903.2000.01.010","article-title":"Experimental study on protection of renal function by tangweikang capsule in diabetic rats","volume":"6","author":"L","year":"2000","journal-title":"Chin. J. Exp. Traditional Med. Formulae"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e96968","DOI":"10.1172\/jci.insight.96968","article-title":"Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes","volume":"3","author":"Lovshin","year":"2018","journal-title":"JCI Insight"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2215\/cjn.0000000000000205","article-title":"Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis","volume":"18","author":"Luo","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e25991","DOI":"10.1097\/md.0000000000025991","article-title":"Efficacy of combined angiotensin II receptor blocker with tripterygium glycosides on diabetic nephropathy: a protocol for meta-analysis","volume":"100","author":"Ma","year":"2021","journal-title":"Med. Baltim."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2146512","DOI":"10.1080\/0886022x.2022.2146512","article-title":"Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention","volume":"45","author":"Ma","year":"2023","journal-title":"Ren. Fail"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Mart\u00ednez-D\u00edaz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B93","article-title":"A new approach to kidney protection in patients with type 2 diabetes","author":"McGill","year":"2021","journal-title":"EASD Meeting"},{"key":"B94","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s2213-8587(18)30263-8","article-title":"New pharmacological strategies for protecting kidney function in type 2 diabetes","volume":"7","author":"Muskiet","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3760\/cma.j.cn441217-20201125-00041","article-title":"Chinese guidelines for diagnosis and treatment of diabetic kidney disease","volume":"37","author":"Nephrology","year":"2021","journal-title":"Chin. J. Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"105019","DOI":"10.1016\/j.phrs.2020.105019","article-title":"Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases","volume":"159","author":"Nicotera","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1152\/ajprenal.00565.2020","article-title":"DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice","volume":"320","author":"Nistala","year":"2021","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ndt\/gfab167","article-title":"Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease","volume":"38","author":"Ortiz","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"B101","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"Bmj"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/hjh.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Piperidou","year":"2019","journal-title":"J. Hypertens."},{"key":"B104","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.diabet.2014.10.003","article-title":"The impact of hyperfiltration on the diabetic kidney","volume":"41","author":"Premaratne","year":"2015","journal-title":"Diabetes and metabolism"},{"key":"B105","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3760\/cma.j.cn431460-20210708-00185","article-title":"Effect of keluoxin capsule combined with losartan potassium on elderly diabetic nephropathy and its effect on proteinuria","volume":"42","author":"Qianqin","year":"2022","journal-title":"Int. J. Urology Nephrol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/mnh.0000000000000785","article-title":"Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease","volume":"31","author":"Raj","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B107","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/s41598-019-52390-4","article-title":"Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: an in vitro- in vivo Assessment","volume":"9","author":"Raval","year":"2019","journal-title":"Sci. Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"B109","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"","journal-title":"Kidney Int."},{"key":"B110","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"","journal-title":"Kidney Int. Rep."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.7501\/j.issn.1674-5515.2020.09.006","article-title":"Clinical study on Keluoxin Capsules combined with benazepril in treatment of diabetic nephropathy","volume":"35","author":"Shanshan","year":"2020","journal-title":"Drugs and Clin."},{"key":"B113","doi-asserted-by":"publisher","first-page":"774414","DOI":"10.3389\/fphar.2021.774414","article-title":"New insights into the effects of individual Chinese herbal medicines on chronic kidney disease","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000515809","article-title":"The effect of amiloride on proteinuria in patients with proteinuric kidney disease","volume":"52","author":"Shen","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2147\/dddt.S367624","article-title":"Quality of evidence supporting the role of tripterygium glycosides for the treatment of diabetic kidney disease: an overview of systematic reviews and meta-analyses","volume":"16","author":"Shi","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/1751-7915.14200","article-title":"Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice","volume":"16","author":"Shi","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.exger.2012.11.006","article-title":"N-acetylcysteine attenuates renal alterations induced by senescence in the rat","volume":"48","author":"Shimizu","year":"2013","journal-title":"Exp. Gerontol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/mnh.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B119","doi-asserted-by":"publisher","first-page":"18832","DOI":"10.1039\/d0ra09874d","article-title":"Detection of urinary microRNA biomarkers using diazo sulfonamide-modified screen printed carbon electrodes","volume":"11","author":"Smith","year":"2021","journal-title":"RSC Adv."},{"key":"B120","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3760\/cma.j.cn115791-20210221-00095","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)","volume":"13","author":"Society","year":"2021","journal-title":"Chin. J. Diabetes Mellit."},{"key":"B121","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3969\/j.issn.1003-8914.2023.01.039","article-title":"The clinical effect of yishen Huashi granules combined with dapagliflozin and its influence on quality of life of diabetic nephropathy","volume":"38","author":"Song","year":"2023","journal-title":"Guangming J. Chin. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1177\/1060028019843644","article-title":"Nondihydropyridine calcium channel blockers for the treatment of proteinuria: a review of the literature","volume":"53","author":"Steuber","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"B123","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1139\/cjpp-2022-0082","article-title":"Lack of renoprotective effects of targeting the endothelin A receptor and (or) sodium glucose transporter 2 in a mouse model of Type 2 diabetic kidney disease","volume":"100","author":"Stuart","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/13543784.2016.1241764","article-title":"Investigational calcium channel blockers for the treatment of hypertension","volume":"25","author":"Tamargo","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1166880","DOI":"10.3389\/fendo.2023.1166880","article-title":"Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study","volume":"14","author":"Tan","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B126","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/13880209.2020.1711782","article-title":"Panax notoginseng preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Tang","year":"2020","journal-title":"Pharm. Biol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cphy.c170048","article-title":"ATP-sensitive potassium channels and their physiological and pathophysiological roles","volume":"8","author":"Tinker","year":"2018","journal-title":"Compr. Physiol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int."},{"key":"B129","doi-asserted-by":"publisher","first-page":"111918","DOI":"10.1016\/j.biopha.2021.111918","article-title":"New progress in drugs treatment of diabetic kidney disease","volume":"141","author":"Wang","year":"","journal-title":"Biomed. Pharmacother."},{"key":"B130","doi-asserted-by":"publisher","first-page":"113817","DOI":"10.1016\/j.jep.2021.113817","article-title":"Network pharmacology combined with metabolomics to study the mechanism of Shenyan Kangfu Tablets in the treatment of diabetic nephropathy","volume":"270","author":"Wang","year":"","journal-title":"J. Ethnopharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14728222.2019.1624721","article-title":"Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies","volume":"23","author":"Warren","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"B132","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"6","DOI":"10.19852\/j.cnki.jtcm.2023.01.004","article-title":"Effects of the Huangkui capsule on chronic kidney disease: a systematic review and Meta-analysis","volume":"43","author":"Wei","year":"2023","journal-title":"J. Tradit. Chin. Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1052852","DOI":"10.3389\/fphar.2022.1052852","article-title":"Efficacy and safety of Keluoxin capsule in combination with Western medicine for diabetic kidney disease: a systematic review and meta-analysis","volume":"13","author":"Wenhua","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1195364","DOI":"10.3389\/fphar.2023.1195364","article-title":"Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20202391","article-title":"Efficacy of tripterygium glycosides combined with ARB on diabetic nephropathy: a meta-analysis","volume":"40","author":"Wu","year":"2020","journal-title":"Biosci. Rep."},{"key":"B137","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3969\/j.issn.1671-2390.2014.02.009","article-title":"Protective effect of Keluoxin capsule on the renal tubules in patients with early diabetic kidney disease","volume":"14","author":"Xianhong","year":"2014","journal-title":"J. Clin. Nephrol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e13844","DOI":"10.1111\/apha.13844","article-title":"Rodent models to study sodium retention in experimental nephrotic syndrome","volume":"235","author":"Xiao","year":"2022","journal-title":"Acta Physiol. (Oxf)"},{"key":"B139","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clinthera.2021.12.006","article-title":"Therapeutic effect and safety of tripterygium glycosides combined with western medicine on type 2 diabetic kidney disease: a meta-analysis","volume":"44","author":"Xie","year":"2022","journal-title":"Clin. Ther."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.11842\/wst.20220107008","article-title":"Effect of keluoxin on oxidative stress and inflammatory response in the kidney of type 2 diabetic nephropathy rats model","volume":"25","author":"Xm","year":"2023","journal-title":"World Sci. Technology-Modernization Traditional Chin. Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"35969","DOI":"10.1039\/c9ra05046a","article-title":"Effects of Bailing capsule on diabetic nephropathy based on UPLC-MS urine metabolomics","volume":"9","author":"Xu","year":"2019","journal-title":"RSC Adv."},{"key":"B142","doi-asserted-by":"publisher","first-page":"154531","DOI":"10.1016\/j.phymed.2022.154531","article-title":"The effects of Ophiocordyceps sinensis combined with ACEI\/ARB on diabetic kidney disease: a systematic review and meta-analysis","volume":"108","author":"Yan","year":"2023","journal-title":"Phytomedicine"},{"key":"B143","doi-asserted-by":"publisher","first-page":"8455709","DOI":"10.1155\/2021\/8455709","article-title":"Protective effect of keluoxin against diabetic nephropathy in type 2 diabetic mellitus models","volume":"2021","author":"Yang","year":"2021","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"E531","DOI":"10.1152\/ajpendo.00022.2023","article-title":"Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"324","author":"Yao","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s41440-023-01169-2","article-title":"Significance of podocyte DNA damage and glomerular DNA methylation in CKD patients with proteinuria","volume":"46","author":"Yoshimoto","year":"2023","journal-title":"Hypertens. Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"9671768","DOI":"10.1155\/2022\/9671768","article-title":"Efficacy and safety of jinshuibao capsule in diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Yu","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ijpharm.2017.06.070","article-title":"Combination of coenzyme Q10-loaded liposomes with ultrasound targeted microbubbles destruction (UTMD) for early theranostics of diabetic nephropathy","volume":"528","author":"Yue","year":"2017","journal-title":"Int. J. Pharm."},{"key":"B148","doi-asserted-by":"publisher","first-page":"91","DOI":"10.16658\/j.cnki.1672-4062.2024.01.091","article-title":"Clinical study of urine duqing granule combined with valsartan capsule in the treatment of diabetic nephropathy with massive proteinuria","volume":"27","author":"Zeqiong","year":"2024","journal-title":"Diabetes New World"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e34575","DOI":"10.1097\/md.0000000000034575","article-title":"Efficacy of Jinshuibao as an adjuvant treatment for chronic renal failure in China: a meta-analysis","volume":"102","author":"Zhang","year":"","journal-title":"Med. Baltim."},{"key":"B150","doi-asserted-by":"publisher","first-page":"115028","DOI":"10.1016\/j.jpba.2022.115028","article-title":"Tripterygium glycoside tablet attenuates renal function impairment in diabetic nephropathy mice by regulating triglyceride metabolism","volume":"221","author":"Zhang","year":"","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B151","doi-asserted-by":"publisher","first-page":"106111","DOI":"10.1016\/j.phrs.2022.106111","article-title":"Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: a systematic review and network meta-analysis","volume":"177","author":"Zhang","year":"","journal-title":"Pharmacol. Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"915592","DOI":"10.3389\/fphar.2022.915592","article-title":"Bailing capsule (Cordyceps sinensis) ameliorates renal triglyceride accumulation through the PPAR\u03b1 pathway in diabetic rats","volume":"13","author":"Zhang","year":"","journal-title":"Front. Pharmacol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/jcp.31023","article-title":"Research progress on the role of ET-1 in diabetic kidney disease","volume":"238","author":"Zhang","year":"","journal-title":"J. Cell Physiol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.2337\/dc22-0607","article-title":"Efficacy of combined abelmoschus manihot and irbesartan for reduction of albuminuria in patients with type 2 diabetes and diabetic kidney disease: a multicenter randomized double-blind parallel controlled clinical trial","volume":"45","author":"Zhao","year":"2022","journal-title":"Diabetes Care"},{"key":"B155","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/jicm.2022.0809","article-title":"A prospective, multicentered, randomized, double-blind, placebo-controlled clinical trial of keluoxin capsules in the treatment of microalbuminuria in patients with type 2 early diabetic kidney disease","volume":"30","author":"Zhao","year":"2024","journal-title":"J. Integr. Complement. Med."},{"key":"B156","doi-asserted-by":"publisher","first-page":"116150","DOI":"10.1016\/j.jep.2023.116150","article-title":"Huangkui capsule alleviates doxorubicin-induced proteinuria via protecting against podocyte damage and inhibiting JAK\/STAT signaling","volume":"306","author":"Zhao","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"241","DOI":"10.13193\/j.issn.1673-7717.2020.05.057","article-title":"Clinical observation of niaoduqing granule combined with valsartan capsules in treatment of diabetic nephropathy","volume":"38","author":"Zhigang","year":"2020","journal-title":"Chin. Archives Traditional Chin. Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.aal4178","article-title":"A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models","volume":"358","author":"Zhou","year":"2017","journal-title":"Science"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1349022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:01:57Z","timestamp":1722402117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1349022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":156,"alternative-id":["10.3389\/fphar.2024.1349022"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1349022","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"1349022"}}